Brokers Set Expectations for Equillium FY2029 Earnings

Equillium, Inc. (NASDAQ:EQ) – Leerink Partnrs issued their FY2029 earnings estimates for shares of Equillium in a research note issued on Friday, March 28th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($0.06) per share for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Equillium’s current full-year earnings is $0.14 per share.

Separately, Leerink Partners restated a “market perform” rating and issued a $1.00 price objective (down from $3.00) on shares of Equillium in a research report on Friday, March 28th.

Equillium Trading Up 28.4 %

NASDAQ EQ opened at $0.50 on Monday. The stock has a market capitalization of $17.85 million, a price-to-earnings ratio of -3.60 and a beta of 1.87. The stock has a 50-day moving average of $0.75 and a 200 day moving average of $0.79. Equillium has a twelve month low of $0.36 and a twelve month high of $2.43.

Equillium (NASDAQ:EQ) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. Equillium had a negative net margin of 10.05% and a negative return on equity of 20.68%. The company had revenue of $4.39 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Equillium stock. DCF Advisers LLC raised its position in shares of Equillium, Inc. (NASDAQ:EQ) by 91.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,947 shares of the company’s stock after acquiring an additional 29,985 shares during the quarter. DCF Advisers LLC owned approximately 0.18% of Equillium worth $47,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.